Dr. Cush
Rheumnow Podcast
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Install for free
Android 5M+ downloads · 4.8 rating
iOS soon
Episodes
Giant Cell Arteritis and Polymyalgia Rheumatica Update 13.06.2024 2:39
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New Indications 13.06.2024 2:25
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Top 3 Messages About JAK Inhibitor Safety 13.06.2024 1:58
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Pain in RA: Different Drugs for Different Mechanisms 13.06.2024 6:20
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
JAK Inhibitors for New Indications 13.06.2024 2:25
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA 13.06.2024 6:43
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Treat to Target Outcomes in Early AxSpA 13.06.2024 7:17
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Does Telemonitoring in SpA Work? 13.06.2024 5:39
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
PsA Treatment: is Earlier Better? 13.06.2024 5:07
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New Indications 13.06.2024 2:25
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Transition from Psoriasis to PsA: Can we Prevent It? 13.06.2024 4:39
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
EULAR 2024 Daily Recap - Days 1 & 2 13.06.2024 41:24
Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain 13.06.2024 4:07
Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis 13.06.2024 4:22
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? 13.06.2024 5:04
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Voclosporin and Steroids in Lupus Nephritis 13.06.2024 3:37
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
3 Big Lupus Themes from EULAR 2024 13.06.2024 2:14
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
Does B Cell Depletion Matter? 13.06.2024 5:36
Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? 13.06.2024 3:22
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? 13.06.2024 5:04
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? 13.06.2024 5:04
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Is Cannabis Safe? (6.7.2024) 07.06.2024 21:54
Dr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!
ACR’s Run at Goliath (PCPs) (5.31.2024) 31.05.2024 18:56
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APP's - what do you think?
The Window of Opportunity (5.24.2024) 24.05.2024 20:49
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Don't You Know Who I am (5.17.2024) 17.05.2024 23:56
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This weeks question - Can we prevent gout, ILD or psoriasis?
Similar podcasts
Listen to the Rheumnow Podcast podcast in Replaio
Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.
